moleculent.comCrawled Oct 24, 2026
Each year, more than 300,000 people are diagnosed with melanoma worldwide, and the number is estimated to rise. While mutations in genes like BRAF and NRAS, two of the most common genetic alterations in melanoma, can drive tumor growth, they don’t tell the whole story. Increasingly, research points to the importance of the tumor’s microenvironment—and how melanoma cells interact with their surroundings.
Over the past decade, researchers mapped genomes, identified new cell types, and made remarkable progress in profiling biology at the single-cell level. But the next layer of biological understanding won’t come from studying cells in isolation, it will come from studying what happens between them. To move forward, we need to focus not only on who the cells are, but how they behave in their native context and in communication with each other.
Moleculent launched its Techstart program, offering researchers early access to its platform for profiling cell-cell interactions in FFPE tissue samples.
Moleculent integrates functional biology to advance research in biological studies.
Moleculent secures $20 million in funding to develop technology analyzing cell interactions at the tissue level. The round is led by Rubicon Healthcare Partners, with additional support from ARCH Venture Partners and Eir. The Swedish biotech company aims to deepen understanding of cellular behavior in health and disease.
May 2026ArcticStartupNews article
Moleculent AB secures $20 million in funding to expand its functional profiling platform, which maps cell-cell communication in human tissue. The capital, led by Rubicon Healthcare Partners with support from ARCH Venture Partners and Eir Ventures, will scale the company’s Techstart Early Access Program and accelerate commercial operations in the US. Moleculent specializes in high-throughput analysis of cellular interactions for life sciences research.
Apr 2026MoleculentNews article
Moleculent introduces **Techstart**, an early-access program for its high-plex platform that maps cell-cell interactions in **formalin-fixed paraffin-embedded (FFPE) tissues**, targeting immuno-oncology applications. The platform enables large-scale decoding of cellular communication networks directly within preserved tissue samples. This initiative aims to accelerate research by providing scalable access to advanced interaction mapping tools.
Nov 2025Cancer Research from Technology NetworksNews article
Moleculent is testing its cell-cell mapping technology through an Early Access Program, initially focusing on immuno-oncology applications. The company plans to extend its use to autoimmune diseases and infectious diseases in the future. This technology aims to provide detailed insights into cellular interactions relevant to these medical fields.
Nov 2025GEN - Genetic Engineering and Biotechnology NewsNews article
